Newron Pharmaceuticals (SIX: NWRN)

Currency in CHF

Last close As at 27/09/2023


−0.30 (−5.23%)

Market capitalisation


Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase II/III trial programme targeting schizophrenia.

Xadago is marketed as an add-on to levodopa therapy in PD. It is currently sold in Europe, Japan, the United States and other territories. Generic manufacturers have notified the FDA of their intention to file generic Xadago products. Newron is contesting these filings. Xadago is currently patent protected until at least 2027.

Latest Insights

View More



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Marco Caremi

    Executive VP of Business Development

  • Stefan Weber


Balance Sheet

Forecast net cash (€m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual 2.3 (11.7) 325.0
Relative 2.3 (10.2) 290.8
52 week high/low CHF8.0/CHF1.1


Newron is developing evenamide as an add-on therapy to treat poorly managed and treatment-resistant schizophrenia (TRS). A potentially pivotal Phase III trial (study 008A) in patients with schizophrenia who are taking antipsychotics but not classified as having TRS is underway with readouts expected by end-2023 or early 2024. In the Phase II trial (study 014/015) for patients with TRS, evenamide has demonstrated both safety and efficacy in readouts to date. Six-month results from the full 161-patient cohort in extension study 015 are expected in October 2023, and full one-year data are expected in Q124. Newron intends to begin an additional, potentially pivotal, multinational Phase III study (study 003) in TRS patients (expected to start in H223). In its H123 results, Newron recorded total revenue of €5.5m for the period, nearly double H122’s revenue of €2.8m, primarily driven by higher royalty income for Xadago.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2021A 5.8 (11.4) (14.1) (79.23) N/A N/A
2022A 6.1 (12.6) (17.0) (95.34) N/A N/A
2023E 8.9 (11.7) (14.6) (81.90) N/A N/A
2024E 6.8 (19.1) (22.3) (124.77) N/A N/A

Further insights



Deutsches Eigenkapitalforum (EKF) 2022 healthcare



Deutsches Eigenkapitalforum (EKF) 2022

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest




ASCO 2023 key takeaways



Machine learning in drug development

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free